Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin
A quarter of patients fail to stomach survodutide.
Easl 2023 – GLP-1 combos take on a milder form of Nash
Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.